Dr. Steven Hatfill is a specialist physician and a virologist with a military background and separate master’s degrees in microbial genetics, radiation biochemistry, and experimental pathology. In 1986, he overwintered in Antarctica as a member of the 27th SANAE Antarctic Expedition. In 1992, he demonstrated that the drug Thalidomide exerted a major effect in Leukemia cell cultures. Analogues of this drug are now a mainstay treatment for pre-leukemia and Multiple Myeloma.
Dr Hatfill’s medical fellowships include Oxford University, the NIH in Bethesda, and the NRC where he studied the Ebola Virus at the US Army Medical Research Institute for Infectious Diseases at Fort Detrick. His background includes training and certification as a UN Weapons Inspector. Since 2005, he has been involved in the directed training of both civilians and the military, in the medical response to mass casualties from blast and ballistic injury.
In 2015, he trained and helped to establish the Rapid Hemorrhagic Fever Response Team for the National Disaster Management Unit in Kenya, Africa. He has numerous peer-reviewed scientific publications. In 2018, he was awarded Honorary U.S. Army Parachute Wings with Bronze Star, in an exchange ceremony with the U.S. Army 1st Special Warfare Training Group (Airborne). He is a National Fellow of the Explorers Club, a board member of several non-profit medical organizations and is an Adjunct Assistant Professor in two departments at a leading US Medical School.